STOCK TITAN

Vyome Holdings (Nasdaq: HIND) unit Livechain acquires Humanyze senior debt

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Vyome Holdings, Inc., through subsidiary Livechain, Inc. and its unit LICH Inc., entered a Notes Purchase and Exchange Agreement to acquire senior secured convertible notes of Humanyze with aggregate principal of $5,765,000 from Remus Capital.

As consideration, Livechain will issue 211,200,844 shares of its common stock to Remus, equal to 25% of Livechain’s fully diluted common stock immediately before closing, and reserve up to 84,480,338 additional shares (10%) for compensatory grants to key and future employees. After closing, substantially all Humanyze assets and operations are expected to be transferred to the buyer entity in satisfaction of the notes.

The agreement, a related party transaction, was approved by Vyome’s audit committee and board with interested Remus-affiliated directors recusing themselves, and the outside closing date was amended to March 8, 2026. A press release states the Livechain stock issued in the transaction is valued at approximately $325,000.

Positive

  • None.

Negative

  • None.

Insights

Vyome pivots deeper into AI HR analytics via a related-party, largely stock-based Humanyze debt acquisition.

Vyome, through subsidiary Livechain, is acquiring senior secured convertible notes of Humanyze with $5,765,000 principal from Remus in exchange for Livechain common stock. The press release cites an approximate equity value of $325,000, suggesting the notes are being purchased at a substantial discount to face value.

Remus will receive 211,200,844 Livechain shares, or 25% of fully diluted equity immediately pre-closing, and Livechain is reserving up to 84,480,338 additional shares (10%) for compensatory grants. This structure concentrates Humanyze exposure within Livechain while potentially creating meaningful equity overhang at the subsidiary level rather than at Vyome directly.

The deal is a related party transaction but was reviewed and approved by Vyome’s audit committee and board, with Remus-affiliated directors recusing themselves. Actual value realization depends on integrating Humanyze’s AI HR analytics business and Livechain’s ability to raise capital, as referenced by management’s stated efforts in the agreement and comments about positioning for a potential uplisting in 2026.

false 0001427570 0001427570 2026-02-20 2026-02-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 20, 2026

 

VYOME HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   1-37897   26-1828101
(State or other jurisdiction
of incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification Number)

 

Harvard Square, One Mifflin Place, Suite 400

Cambridge, MA

 

02138

(Address of principal executive offices)   (Zip Code)

 

(949) 429-6680

(Registrant’s telephone number, including area code)

 

Not applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Class   Trading Symbol   Name of Exchange on which Registered
Common stock, $0.001 par value per share   HIND   The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement

 

Notes Purchase and Exchange Agreement

 

As previously reported, on December 17, 2025, Vyome Holdings, Inc. (the “Company”) entered into a binding letter of intent (the “LOI”) regarding a proposed transaction pursuant to which the Company and LiveChain, Inc. (“LICH”), an indirect subsidiary of the Company, agreed to execute definitive agreements to acquire a senior secured convertible note issued by Sociometric Solutions, Inc., d/b/a Humanyze (“Humanyze”) and held by Remus Capital Series B II, L.P. (“Remus”) in exchange for the issuance to Remus of shares of common stock of LICH.

 

As of February 20, 2026, pursuant to the terms of the LOI, the Company entered into a Notes Purchase and Exchange Agreement (the “Agreement”) by and among LICH, LICH AI Inc. (the “Buyer”), a subsidiary of LICH, and Remus to effectuate the transactions contemplated by the LOI. Pursuant to the Agreement, the Buyer will acquire senior secured convertible notes in the aggregate principal amount of $5,765,000 (the “Notes”) issued by Humanyze and held by Remus. As consideration, LICH will issue to Remus 211,200,844 shares of its common stock, representing 25% of the fully diluted common stock of LICH immediately prior to Closing (as defined in the Agreement). The parties further agreed that immediately following the Closing, all or substantially all of the assets and operations of Humanyze shall be transferred to the Buyer, in full satisfaction of the amounts due and payable to the Buyer under the Notes.

 

The Agreement provides for the reservation for issuance of up to an additional 84,480,338 shares of LICH’s common stock, representing 10% of the fully diluted common stock of LICH immediately prior to Closing, to key and future employees of LICH (the “Compensatory Shares”). LICH agreed to certain future issuances to Remus, upon issuance of shares by LICH as compensation in consideration of services provided to LICH which obligation to Remus shall terminate upon the earlier of (i) the second anniversary of the Closing; and (ii) the issuance of the Compensatory Shares.

 

Following the Closing, Remus agreed to ensure that Humanyze remains active and in good standing for purposes of servicing select existing debts, liabilities, and other obligations. In addition, the LICH board of directors and its CEO will use commercially reasonable efforts to raise capital as needed for LICH and/or the Buyer.

 

The Agreement contains customary representations, warranties and agreements by the parties and customary conditions to closing and obligations of the parties and indemnification provisions. In addition, the Agreement provides for certain termination provisions, including the right of either LICH or Remus to terminate the Agreement in the event that the closing of the transactions contemplated thereby shall not have occurred on or before a certain date (the “Outside Date”). On February 25, 2026, the parties amended the Agreement to update the Outside Date to March 8, 2026.

 

The Agreement and the transactions contemplated thereunder constitute a related party transaction. Accordingly, the Agreement was reviewed and approved by the Audit Committee of the Board of Directors of the Company prior to its execution. Krishna K. Gupta (founder and CEO of Remus) and John Tincoff (a partner of Remus) recused themselves from the Audit Committee’s deliberations with respect to the Agreement. The Agreement was also reviewed and approved by the Company’s Board of Directors prior to its execution. Mr. Gupta (founder and CEO of Remus), Stash Pomichter (a partner of Remus) and Mr. Tincoff (a partner of Remus) recused themselves from the Board of Directors’ deliberations with respect to the Agreement.

 

The foregoing description of the Agreement is qualified in its entirety by reference to the full text of the Agreement, a copy of which is attached hereto as Exhibit 10.1 and is incorporated herein in its entirety by reference.

 

Item 8.01 Other Events.

 

On February 24, 2026, the Company issued a press release announcing its entry into the Agreement. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K, and the information set forth therein is incorporated herein by reference and constitutes a part of this report.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
10.1*   Notes Purchase and Exchange Agreement, dated February 20, 2026, by and among Vyome Holdings, Inc., LiveChain, Inc., LICH AI, Inc., and Remus Capital Series B II, L.P.
99.1   Press Release issued February 24, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

*The schedules and exhibits to this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VYOME HOLDINGS, INC.
     
  By: /s/ Venkat Nelabhotla
    Venkat Nelabhotla
    President & Chief Executive Officer

 

Dated: February 25, 2026

 

2

 

Exhibit 99.1

 

Livechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company

 

Livechain Creates Path to Seek Potential Uplisting to National Exchange in 2026

 

CAMBRIDGE, MA - Livechain, Inc (“Livechain”) (OTCX: LICH), a subsidiary of Vyome Holdings, Inc (“Vyome”) (Nasdaq: HIND), announced today that it has executed a debt purchase agreement with Remus Capital, a leading AI-focused venture capital firm, in order to acquire Sociometric Solutions, Inc, d/b/a, Humanyze (“Humanyze”), a rapidly emerging human resources data and analytics company.

 

The transaction was structured as an all-stock transaction in which LICH issued shares of its common stock, valued at approximately $325,000, in exchange for acquiring a senior, secured convertible note issued to Remus by Humanyze. Through this transaction, LICH has initiated a default and asset transfer in order to assume all business assets, including intellectual property and trade secrets, and to take direct control of the daily operations of Humanyze.

 

Born from the prestigious MIT Media Lab, Humanyze is working to redefine the future of work through science-backed analytics and AI-enabled, data-driven insights that help large, complex companies make continuous workplace improvements that benefit both employees and the businesses.

 

“First of all, this transaction transforms Livechain, driving it into an exciting and rapidly evolving AI HR space, creating a path for uplisting to a national exchange, and giving it the potential to generate real value for its shareholders. Second, the value creation under Livechain also has the potential to deliver real and lasting value to the shareholders of Vyome. As the majority shareholder of Livechain, Vyome stands to benefit significantly from any value created under Livechain. Our focus is on shareholder value, and our desire is that as Livechain’s underlying value increases, Vyome will be positioned to increase its Livechain equity position,” said Krishna Gupta, Chairman of Vyome.

 

“Humanyze is attacking one of the biggest issues facing Fortune 1000 companies around the world – human capital, and the cost of developing, retaining, and rewarding people in the most cost-effective way possible, all of which is even more important in an AI-first world. We see multiple ways for Humanyze to create value and position Livechain for an uplisting to a national exchange. Livechain will have its own team and plans to have its own capital on a go-forward basis. We do not anticipate that Livechain will be using any capital or operational bandwidth of Vyome,” said Venkat Nelabhotla, CEO of Vyome and board member of Livechain.

 

Humanyze has built a compelling AI-enabled platform that breaks down critical employment-driven data to give employers clear, actionable data that contributes not only to the tangible bottom line but also to the optimization of many companies’ most valuable resources, their human capital.

 

About Livechain, Inc.

 

Livechain is currently focused on pursuing strategic alternatives in emerging technology sectors. Livechain intends to enter the artificial intelligence space through the planned acquisition of AI-driven assets focused on human capital, workforce intelligence, and human relationship management. Additionally, Livechain seeks to evaluate additional synergistic opportunities in order to build a scalable AI platform related to its pursuits.

 

 

 

 

Livechain Forward-Looking Statement Disclosure

 

This press release contains statements that do not relate to historical facts but are "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can generally (although not always) be identified by their use of terms and phrases such as anticipate, appear, believe, continue, could, estimate, expect, indicate, intend, may, plan, possible, predict, project, pursue, will, would and other similar terms and phrases, as well as the use of the future tense. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations, and assumptions regarding the future of the business of the Livechain, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Forward-looking statements in this press release speak only as of the date hereof. Unless otherwise required by law, we undertake no obligation to publicly update or revise these forward-looking statements, whether because of new information, future events, or otherwise.

 

About Vyome Holdings, Inc.

 

Vyome is building the world’s premier platform spanning the US-India innovation corridor. Based in Cambridge, MA, Vyome’s immediate focus is on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. To learn more, please visit www.vyometx.com

 

Vyome Forward-Looking Statements

 

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project,” “outlook,” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such statements include, but are not limited to, statements contained in this press release relating to Vyome’s business strategy, Vyome’s future operating results, and liquidity and capital resources outlook. Forward-looking statements are based on Vyome’s current expectations and assumptions regarding Vyome’s business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Vyome’s actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. Vyome cautions you, therefore, against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, Vyome’s ability to raise capital to fund continuing operations; its ability to protect Vyome’s intellectual property rights; the impact of any infringement actions or other litigation brought against Vyome; competition from other providers and products; Vyome’s ability to develop and commercialize products and services; changes in government regulation; Vyome’s ability to complete capital raising transactions; and other factors relating to Vyome’s industry, operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause Vyome’s actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. Vyome assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release, except as may be required under applicable securities law.

 

Media and Investor Relations Contact

contact@vyometx.com

 

Visit us on social media:

Facebook
X
LinkedIn

 

 

 

 

FAQ

What transaction did Vyome Holdings (HIND) announce involving Livechain and Humanyze?

Vyome Holdings announced that subsidiary Livechain, through LICH Inc., agreed to acquire senior secured convertible notes of Humanyze with $5,765,000 principal from Remus. In return, Livechain will issue common stock and then receive substantially all Humanyze assets and operations via an asset transfer.

How much stock is Livechain issuing to Remus in the Humanyze deal?

Livechain will issue 211,200,844 shares of its common stock to Remus, representing 25% of Livechain’s fully diluted common stock immediately prior to closing. The agreement also reserves up to 84,480,338 additional shares (10%) for future compensatory grants to key and future employees.

What is the implied value of Livechain shares issued in the Humanyze transaction?

The accompanying press release states that Livechain issued common stock valued at approximately $325,000 in the all-stock transaction. This equity was exchanged for senior secured convertible notes of Humanyze with aggregate principal of $5,765,000, indicating the consideration is well below face value of the debt.

Why is the Humanyze transaction considered a related party deal for Vyome Holdings (HIND)?

The transaction is related party because Remus Capital, the noteholder, has principals who also hold roles at Vyome, including Krishna Gupta and others. Vyome’s audit committee and full board reviewed and approved the agreement, with all Remus-affiliated directors recusing themselves from the deliberations and approvals.

What are the key share reservations for employees in the Livechain–Humanyze structure?

The agreement reserves for issuance up to 84,480,338 shares of Livechain common stock, equal to 10% of fully diluted shares immediately prior to closing. These potential “Compensatory Shares” are designated for key and future employees as equity-based incentives linked to Livechain’s ongoing operations.

What happens to Humanyze’s assets after the Livechain note acquisition closes?

Immediately following closing, all or substantially all of Humanyze assets and operations are expected to be transferred to the buyer entity controlled by Livechain. This transfer is intended to fully satisfy amounts due under the acquired notes and give Livechain direct control of Humanyze’s business and intellectual property.

What is the updated outside date for closing the Livechain–Humanyze transaction?

The parties amended their agreement to change the outside closing deadline to March 8, 2026. Either Livechain or Remus may terminate the agreement if the contemplated transactions have not closed by that Outside Date, subject to the specific termination provisions included in the agreement.

Filing Exhibits & Attachments

5 documents
ReShape Lifesciences Inc.

NASDAQ:RSLS

RSLS Rankings

RSLS Latest News

RSLS Latest SEC Filings

RSLS Stock Data

7.64M
5.48M
Medical Devices
Pharmaceutical Preparations
Link
United States
SAN CLEMENTE